Acinetobacter baumannii Infection Models

TransPharm Preclinical Solutions performs preclinical efficacy testing of antibacterial candidates against Acinetobacter baumannii (A. baumannii) using validated in vivo infection models in mice and rats. If you are developing an antibiotic, biologic, or alternative therapeutic that works against A. baumannii, and you need in vivo efficacy data across clinically relevant disease presentations, these models are built to generate the quantitative, decision-grade evidence that your program requires.

A. baumannii is an aerobic, Gram-negative coccobacillus and a prolific biofilm former. It is an opportunistic, predominantly healthcare-associated pathogen: infections tend to be concentrated in critically ill and hospitalized patients, particularly those who are mechanically ventilated, have open wounds or burns, indwelling devices, or prior antibiotic exposure. The organism’s ability to persist on dry surfaces and medical equipment and to withstand desiccation plays a large role in outbreaks, facilitating its transmission through hospital environments.

As one of the six ESKAPE pathogens and a designated critical-priority organism for antibiotic research, A. baumannii presents severe disease in vulnerable patients and has a shrinking set of effective therapies. Multidrug-resistant strains are increasingly common and carry high mortality rates. This clinical reality is what makes robust, reproducible preclinical models essential to advancing the next generation of anti-infectives.

In immunocompetent hosts, A. baumannii frequently produces only self-limiting infection, which can mask a true therapeutic effect and undermine the ability to measure efficacy. TransPharm Preclinical Solutions’s models are validated to generate consistent, high-burden infection suitable for pharmacodynamic assessment.

The available models span the major clinical presentations of A. baumannii disease, so a candidate can be tested against the infection type most relevant to its intended use:

• Dermal Infection – Deep Wound
• Peritonitis
• Pulmonary Infection
• Soft Tissue Infection

This breadth lets sponsors align preclinical evidence with a target indication rather than relying on a single generic model.

TransPharm Preclinical Solutions has validated A. baumannii studies using the reference strain ATCC 17961, validated across all four models, and MMX 6970 in the deep wound model. TransPharm Preclinical Solutions also maintains an on-site library of hundreds of validated pathogens, including many multidrug-resistant (MDR) strains; additional strains – including sponsor-supplied isolates or characterized resistant clinical isolates – can be sourced and validated to a program’s specifications upon request. Studies are available in both mice and rats, depending on the model.

Every study parameter is configurable to the scientific question: animal species (mouse or rat, model dependent), challenge strain, route of administration, comparator agents, and dosing schedule. The core readouts across all models are quantitative bacterial burden (CFU/g or CFU/mL) in target tissues, organs, and blood, and, where applicable, survival and mortality tracking.

The following are available as add-ons to any study:

• Pharmacokinetic profiling and PK/PD analysis
• Blood chemistry
• Additional tissue harvests
• Histopathology

A full-thickness wound is created with a 6 mm biopsy punch over the dorsal thoracic region, and an A. baumannii broth culture is inoculated directly into the wound bed. Test article can be delivered topically or by oral gavage (PO), subcutaneous (SC), intraperitoneal (IP), or intravenous (IV) routes, supporting evaluation of both local and systemic therapies. The primary endpoint is bacterial burden (CFU/g) in harvested skin. Validated in mice; rat validation available upon request.

Animals are challenged by intraperitoneal injection, with gastric mucin used to help establish infection where needed. Endpoints include survival (mortality tracking) and CFU burden in harvested organs and blood, supporting both lethality- and burden-based efficacy readouts. Validated in mice and rats.

Infection is established by intranasal (IN) or intratracheal (IT) instillation, modeling the respiratory disease for which A. baumannii is clinically notorious. Endpoints include survival and CFU burden in the lungs and other harvested tissues. TransPharm Preclinical Solutions’s pulmonary model produces a robust, high-burden infection to which vehicle-treated animals succumb rapidly, providing a stringent in vivo test of therapeutic efficacy. Validated in mice and rats.

Animals are challenged by intramuscular injection into one or both quadriceps – a configuration well suited to pharmacokinetic/pharmacodynamic characterization. Endpoints include bacterial burden in muscle and other harvested tissues, with survival tracking available. Validated in mice.

Across these models, TransPharm Preclinical Solutions’s A. baumannii studies have discriminated efficacy for comparators spanning multiple drug classes – including carbapenems, fluoroquinolones, and glycylcyclines – confirming models sensitive enough to distinguish active from inactive therapy.

Beyond in vivo models, TransPharm Preclinical Solutions performs in vitro susceptibility and activity testing against A. baumannii: minimum inhibitory concentration (MIC) by agar and broth dilution per CLSI, minimum bactericidal concentration (MBC), time-kill kinetics, and checkerboard analysis/synergy testing. Checkerboard analysis is especially relevant for resistant isolates, where combination regimens are often required.